Author:
Gertz M A,Kumar S K,Lacy M Q,Dispenzieri A,Hayman S R,Buadi F K,Dingli D,Gastineau D A,Winters J L,Litzow M R
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference35 articles.
1. Bjorkstrand B, Gahrton G . High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. Semin Hematol 2007; 44: 227–233.
2. Jagannath S . Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 7 (Suppl 5): S207–S214.
3. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A et al. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 2007; 47: 2153–2160.
4. Jacoub JF, Suryadevara U, Pereyra V, Colon D, Fontelonga A, Mackintosh FR et al. Mobilization strategies for the collection of peripheral blood progenitor cells: results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443–1450.
5. Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–697.